skip to Main Content

TAGline Spring 2015

On Targets and Timelines: With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization and strengthened accountability among all stakeholders.
Read more

Generics vs. the Giant

For people with drug-resistant tuberculosis (DR-TB), generic linezolid may be a lifesaver. But only if quality-assured versions are available and affordable Erica Lessem As new drugs bedaquiline and delamanid offer renewed hope of treating DR-TB, doctors and programs are faced…

Read more

Safeguarding against Stock-Outs

The time has come for U.S. tuberculosis programs to have full access to the Stop TB Partnership’s Global Drug Facility procurement and stockpile safety nets Kenyon Farrow Generic drugs can be credited with saving millions of lives by allowing for…

Read more

The Road to Treatment Access

Generic drug registration, licensing, and a trip to Gilead’s islands Karyn Kaplan and Tracy Swan Access to essential medicines is part of the human right to health. The HIV/AIDS epidemic has demonstrated that generic competition is key to massive antiretroviral…

Read more

A Drug by Any Other Name

The basics of generic medications, bioequivalence, and the push for good manufacturing practices Tim Horn Securing access to generic drugs to treat HIV, hepatitis C virus (HCV), and tuberculosis (TB) is now one of the most prominent strategies of global…

Read more
Back To Top